Parkinson Disease Neuroprotection Clinical Trial: Clinical Centers

The summary for the Parkinson Disease Neuroprotection Clinical Trial: Clinical Centers grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Parkinson Disease Neuroprotection Clinical Trial: Clinical Centers: The Neurodegeneration and Clinical Trial Groups of the National Institute of Neurological Disorders and Stroke (NINDS) request applications for additional clinical centers to collaborate in clinical trials to test potential neuroprotective agents in Parkinsons disease (PD). These studies, the neuroprotection exploratory trials in PD (NET- PD) include pilot clinical trials and plans for a large, simple phase III clinical trial. Previous solicitations were issued for the clinical and statistical coordinating centers (http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-01-012.html) and clinical centers (http://grants.nih.gov/grants/guide/rfa-files/RFA-NS-02-010.html. Pilot clinical trials are ongoing with over forty participating sites. The agents under study currently include creatine, minocycline, Coenzyme Q10, and a neuroimmunophilin ligand. These pilot studies are expected to complete follow-up in the 3rd quarter of 2005. Depending upon the results of these studies a phase III trial with one of these agents may be conducted or additional pilot studies of different agents may be performed. Sites are sought to join NET-PD to participate in these future studies.

Federal Grant Title:	Parkinson Disease Neuroprotection Clinical Trial: Clinical Centers
Federal Agency Name:	National Institutes of Health
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-NS-05-004
Type of Funding:	Cooperative Agreement
CFDA Numbers:	93.853
CFDA Descriptions:	Extramural Research Programs in the Neurosciences and Neurological Disorders
Current Application Deadline:	No deadline provided
Original Application Deadline:	Jan 24, 2005
Posted Date:	Sep 08, 2004
Creation Date:	Sep 08, 2004
Archive Date:	Feb 23, 2005
Total Program Funding:	$1,200,000
Maximum Federal Grant Award:	$73,500
Minimum Federal Grant Award:
Expected Number of Awards:	12
Cost Sharing or Matching:	No

Applicants Eligible for this Grant: Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Small businesses Public and State controlled institutions of higher education Private institutions of higher education State governments County governments City or township governments Special district governments Independent school districts Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification)
Additional Information on Eligibility: Eligible agencies of the Federal Government are eligible to apply. Foreign institutions are eligible to apply.
Link to Full Grant Announcement: Information not provided
Grant Announcement Contact: If you have any problems linking to this funding announcement, please contact the NIH OER Webmaster [email protected] NIH OER Webmaster
Similar Government Grants: • Human Leukocyte Antigen (HLA) and Killer-cell Immunoglobulin-like Receptor (KIR) Region Ge...; • Neuropathological Interactions Between COVID-19 and ADRD (R01 - Clinical Trial Not Allowed...; • Protective Strategies to Reduce Amyloid Related Imaging Abnormalities (ARIA) After Anti-Am...; • Mechanistic and Hemodynamic Basis of Diffuse White Matter Disease in Vascular Contribution...; • Tools and resources to understand the vascular pathophysiology of in vivo neuroimaging fin...; • NINDS Cooperative Small Business Awards In Translational Research (SBIR/U44); • NINDS Institutional Center Core Grants to Support Neuroscience Research; • Career Development Award to Promote Diversity in Neuroscience Research
More Grants from the National Institutes of Health: • SBIR Phase IIB Bridge Awards to Accelerate the Development of Cancer-Relevant Technologies...; • Small Business Transition Grant For Early Career Scientists (R41/R42 Clinical Trial Not Al...; • Cystic Fibrosis Research and Translation Centers (P30 Clinical Trial Optional); • Mentored Quantitative Research Development Award (Parent K25 Independent Clinical Trial No...; • Mentored Quantitative Research Development Award (Parent K25 Independent Basic Experimenta...